Emerging Infectious Diseases (Feb 2014)

Fungal Endophthalmitis Associated with Compounded Products

  • Christina A. Mikosz,
  • Rachel M. Smith,
  • Moon Kim,
  • Clara Tyson,
  • Ellen H. Lee,
  • Eleanor Adams,
  • Susanne Straif-Bourgeois,
  • Rick Sowadsky,
  • Shannon Arroyo,
  • Yoran Grant-Greene,
  • Julie Duran,
  • Yvonne Vasquez,
  • Byron F. Robinson,
  • Julie R. Harris,
  • Shawn R. Lockhart,
  • Thomas J. Török,
  • Laurene Mascola,
  • Benjamin J. Park

DOI
https://doi.org/10.3201/eid2002.131257
Journal volume & issue
Vol. 20, no. 2
pp. 248 – 256

Abstract

Read online

Fungal endophthalmitis is a rare but serious infection. In March 2012, several cases of probable and laboratory-confirmed fungal endophthalmitis occurring after invasive ocular procedures were reported nationwide. We identified 47 cases in 9 states: 21 patients had been exposed to the intraocular dye Brilliant Blue G (BBG) during retinal surgery, and the other 26 had received an intravitreal injection containing triamcinolone acetonide. Both drugs were produced by Franck’s Compounding Lab (Ocala, FL, USA). Fusarium incarnatum-equiseti species complex mold was identified in specimens from BBG-exposed case-patients and an unopened BBG vial. Bipolaris hawaiiensis mold was identified in specimens from triamcinolone-exposed case-patients. Exposure to either product was the only factor associated with case status. Of 40 case-patients for whom data were available, 39 (98%) lost vision. These concurrent outbreaks, associated with 1 compounding pharmacy, resulted in a product recall. Ensuring safety and integrity of compounded medications is critical for preventing further outbreaks associated with compounded products. Download MP3 Length: 1:42

Keywords